Tags: Isis | arthritis | drug | testing

Isis to Stop Developing Rheumatoid Arthritis Drug

Monday, 05 Aug 2013 07:42 AM

Isis Pharmaceuticals Inc. said it will stop developing its experimental rheumatoid arthritis drug after a mid-stage trial showed the treatment failed to significantly improve the disease symptoms when compared to a placebo.

Patients treated with the drug, called ISIS-CRPRx, had some improvements in symptoms of RA but they were not statistically significant when compared to those of patients receiving a placebo.

The treatment was developed using Isis's "antisense" technology that helps a compound bind to a specific gene in order to interrupt the production of disease-causing proteins.

The company already has regulatory approval for another drug that uses the same technology to treat a rare genetic disorder causing dangerously high levels of "bad" LDL (low-density lipoprotein) cholesterol.

The drug, Kynamro, was approved by the FDA in January.

ISIS-CRPRx was aiming to treat RA by reducing the production of C-reactive protein (CRP), whose levels are dramatically elevated during inflammatory disorders.

The drug is also being tested in another mid-stage trial for the treatment of atrial fibrillation, a heart rhythm disorder. Data from the trial is expected in the first half of 2014, Isis said in a statement on Monday, adding that it would continue to test the drug in other diseases.

Isis shares closed at $29.23 on Friday on the Nasdaq.

© 2017 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Companies
Isis Pharmaceuticals Inc. said it will stop developing its experimental rheumatoid arthritis drug after a mid-stage trial showed the treatment failed to significantly improve the disease symptoms when compared to a placebo.
Isis,arthritis,drug,testing
210
2013-42-05
Monday, 05 Aug 2013 07:42 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved